We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Circassia

News List

Circassia’s COPD drug gets FDA approval pharmatimes
April 02, 2019
Circassia has announced the US Food and Drug Administration (FDA) approval of its chronic obstructive pulmonary disease (COPD) maintenance treatment, Duaklir.
Circassia prepares for potential US launch of nitric oxide product pharmaphorum
February 19, 2019
UK biotech Circassia has said that its partner AIT Therapeutics has held a meeting with the FDA that paves the way for premarket approval of its nitric oxide product for newborn babies with respiratory failure, AirNOvent.
4 years after mega IPO, Circassia set for small-cap exchange fiercebiotech
December 27, 2018
Four years ago, Circassia looked to have ushered in a new era for biotech IPOs on the London Stock Exchange when it raised £200 million ($252 million) to.....
Circassia takes on full US rights to AZ’ Tudorza pharmatimes
December 13, 2018
The firm already promotes the COPD therapy in the US under a profit share arrangement covering the drug and fellow COPD therapy Duaklir (aclidinium/formoterol), established by the two companies in April last year.